Related Experiment Videos

[Methylprednisolone pulse in treatment of childhood chronic inflammatory demyelinating polyneuropathy]

M A Rafai1, F Z Boulaajaj, Z Sekkat

  • 1Service de neurologie- explorations fonctionnelles, CHU Ibn Rochd, quartier des Hôpitaux, 20000 Casablanca, Maroc. neuroblanca@gmail.com

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|August 17, 2010
PubMed

Insights

Methylprednisolone (MP) pulse therapy offers a promising alternative for treating pediatric chronic inflammatory demyelinating polyneuropathy (CIDP). This treatment led to good outcomes and no recurrence in three childhood CIDP cases.

Area of Science:

  • Pediatric Neurology
  • Clinical Electrophysiology
  • Immunomodulatory Therapies

Background:

  • Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder affecting children.
  • Current treatments include intravenous immunoglobulins and oral corticosteroids, but alternatives are sought.
  • Methylprednisolone (MP) pulse therapy is a potential treatment option for pediatric CIDP.

Observation:

  • Three pediatric cases (one male, two females aged 4-7 years) presented with CIDP symptoms.
  • Symptoms included recurring lower limb functional impotence and walking impairment.
  • Clinical, electrophysiological, and cerebrospinal fluid data confirmed CIDP diagnosis.

Findings:

  • All three children received 5-8 pulses of methylprednisolone (MP).
  • Patients showed satisfactory clinical and electrophysiological improvement after MP pulse therapy.
  • No recurrence of CIDP symptoms was observed in the treated children.

Implications:

  • Methylprednisolone (MP) pulse therapy is a viable and effective alternative treatment for childhood CIDP.
  • This therapeutic approach demonstrates good outcomes and prevents recurrence in pediatric patients.
  • Further research into MP pulse therapy for pediatric neuropathies is warranted.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...